Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Ann Surg Oncol. 2015 Jan 22;22(9):3136–3143. doi: 10.1245/s10434-015-4374-x

FIG. 2.

FIG. 2

Association between CD10 expression and OS in patients with epithelioid and all malignant pleural mesotheliomas. a In patients with epithelioid malignant pleural mesothelioma, the OS for patients with positive tumoral CD10 expression (n = 66) was significantly shorter (median OS 14.5 months) than that for patients with negative CD10 expression (n = 82; 17.4 months; p = 0.04). b For all patients with epithelioid and non-epithelioid tumors, the OS for patients with positive tumoral CD10 expression (n = 90) was significantly shorter (median OS 9.8 months) than that for patients with negative CD10 expression (n = 86; 16.9 months; p = 0.001). OS overall survival